MINNEAPOLIS--(BUSINESS WIRE)--Entellus Medical, a Minnesota-based medical technology company, today announced the first enrollment in the FinESS™ Registry, a prospective, post-approval Registry study designed to assess subject rhinosinusitis symptomatic status of up to 500 patients treated with FinESS™ Sinus Treatment over time. Up to 25 medical practices in the U.S. may participate in this Registry.
